Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: August 4, 2026
Subject: Update on Share Repurchase Programme
Novo Nordisk A/S, a global healthcare company headquartered in Denmark, reported on its ongoing share repurchase activities. The company employs approximately 68,800 people across 80 countries and markets products in around 170 countries.
Key Financial Metrics and Capital Allocation
This filing focuses on capital allocation via share buybacks rather than operational financial performance (revenue, profit, or cash flow). Key metrics include:
- Total Repurchase Programme Cap: Up to DKK 15 billion over a 12-month period beginning February 4, 2026.
- Specific Programme (Initiated May 6, 2026): Up to DKK 11,200,000,010.45 for B shares between May 6, 2026, and February 1, 2027.
- Cumulative Spend (Since Feb 4, 2026): DKK 7,533,256,457.
- Cumulative Shares Repurchased (Since Feb 4, 2026): 27,064,179 B shares.
- Average Purchase Price (Since Feb 4, 2026): DKK 278.35 per B share.
- Treasury Shares Held: 44,249,480 B shares (1.0% of total share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
Material Changes and Recent Activity
The filing details transactions executed between July 27, 2026, and August 3, 2026, under the programme initiated on May 6, 2026:
| Date | Shares Purchased | Avg. Price (DKK) | Transaction Value (DKK) |
|---|---|---|---|
| July 27, 2026 | 195,000 | 324.55 | 63,286,944 |
| July 28, 2026 | 190,000 | 330.16 | 62,729,800 |
| July 29, 2026 | 185,000 | 335.98 | 62,155,883 |
| July 30, 2026 | 185,000 | 333.15 | 61,632,345 |
| July 31, 2026 | 200,000 | 315.08 | 63,016,376 |
| August 3, 2026 | 190,000 | 305.61 | 58,066,217 |
| Accumulated (May 6 - Aug 3) | 12,305,000 | - | 3,733,256,468 |
Recent transaction prices ranged from DKK 305.61 to DKK 335.98, indicating volatility in the share price during late July 2026.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the total programme limit of DKK 15 billion during the 12-month period starting February 4, 2026. As of August 3, 2026, approximately DKK 7.53 billion has been utilized, leaving roughly DKK 7.47 billion remaining in the programme.
Regulatory Context: The repurchases are conducted in accordance with Article 5 of Regulation No 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 (Safe Harbour Rules).
Risks and Contingencies: The filing does not disclose specific operational risks, contingencies, or unusual items. It is a routine disclosure of capital return activities.
Investor Verification Checklist
- Verify the remaining capacity of the DKK 15 billion share repurchase programme against the DKK 7.53 billion already spent.
- Monitor the average purchase price (DKK 278.35) relative to current market prices to assess the efficiency of capital return.
- Confirm the impact of the 1.0% treasury share holding on earnings per share (EPS) calculations in future reports.
- Review the full transaction history on novonordisk.com for granular daily execution data.